anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Given the geographical sparsity of Rare Diseases (RDs), assembling a cohort is often a challenging task. Common data models (CDM) can harmonize disparate sources of data that can be the basis of decision support systems and artificial intelligence-based studies, leading to new insights in the field. This work is sought to support the design of large-scale multi-center studies for rare diseases.
METHODS: In an interdisciplinary group, we derived a list of elements of RDs in three medical domains (endocrinology, gastroenterology, and pneumonology) according to specialist knowledge and clinical guidelines in an iterative process. We then defined a RDs data structure that matched all our data elements and built Extract, Transform, Load (ETL) processes to transfer the structure to a joint CDM. To ensure interoperability of our developed CDM and its subsequent usage for further RDs domains, we ultimately mapped it to Observational Medical Outcomes Partnership (OMOP) CDM. We then included a fourth domain, hematology, as a proof-of-concept and mapped an acute myeloid leukemia (AML) dataset to the developed CDM.
RESULTS: We have developed an OMOP-based rare diseases common data model (RD-CDM) using data elements from the three domains (endocrinology, gastroenterology, and pneumonology) and tested the CDM using data from the hematology domain. The total study cohort included 61,697 patients. After aligning our modules with those of Medical Informatics Initiative (MII) Core Dataset (CDS) modules, we leveraged its ETL process. This facilitated the seamless transfer of demographic information, diagnoses, procedures, laboratory results, and medication modules from our RD-CDM to the OMOP. For the phenotypes and genotypes, we developed a second ETL process. We finally derived lessons learned for customizing our RD-CDM for different RDs.
DISCUSSION: This work can serve as a blueprint for other domains as its modularized structure could be extended towards novel data types. An interdisciplinary group of stakeholders that are actively supporting the project's progress is necessary to reach a comprehensive CDM.
CONCLUSION: The customized data structure related to our RD-CDM can be used to perform multi-center studies to test data-driven hypotheses on a larger scale and take advantage of the analytical tools offered by the OHDSI community.
Systems and methods are provided for generating a clinical parameter for a user. A first plurality of wellness-relevant parameters representing the user are monitored at a physiological sensing device over a defined period. A second plurality of wellness-relevant parameters representing the user are obtained via a portable computing device. A third plurality of wellness-relevant parameters representing the user are retrieved from an electronic health records (EHR) system. A set of aggregate parameters are generated from the sets of wellness-relevant parameters, with each of the set of aggregate parameters comprising a unique proper subset of the parameters in the sets of wellness-relevant parameters. A clinical parameter is assigned to the user via a predictive model according to a subset of the set of aggregate parameters. An intervention is provided to the user when the clinical parameter meets a threshold value specific to the patient.
The invention provides a monoclonal antibody for recognizing CD7-CAR molecules and application thereof, wherein the amino acid sequence of a heavy chain CDR3 of the monoclonal antibody is shown as SEQ ID NO. 7, SEQ ID NO. 21 or SEQ ID NO. 35; the amino acid sequence of the light chain CDR3 of the monoclonal antibody is shown as SEQ ID NO. 14, SEQ ID NO. 28 or SEQ ID NO. 42, and the monoclonal antibody for recognizing the CD7-CAR molecule can specifically recognize the CD7-CAR molecule on the CD7-CAR-T cell and has NO cross reaction with other molecules; the monoclonal antibody for recognizing the CD7-CAR molecule has high binding activity with the CD7-CAR molecule, and can accurately, specifically and sensitively detect the transfection efficiency of the CD7-CAR molecule by developing and comprehensively verifying a flow analysis method for detecting the transfection positive rate of the CD7-CAR-T cell CAR.
Liver fibrosis is a determinant-stage process of many chronic liver diseases and affected over 7.9 billion populations worldwide with increasing demands of ideal therapeutic agents. Discovery of active molecules with anti-hepatic fibrosis efficacies presents the most attacking filed. Here, we revealed that hepatic L-aspartate levels were decreased in CCl4-induced fibrotic mice. Instead, supplementation of L-aspartate orally alleviated typical manifestations of liver injury and fibrosis. These therapeutic efficacies were alongside improvements of mitochondrial adaptive oxidation. Notably, treatment with L-aspartate rebalanced hepatic cholesterol-steroid metabolism and reduced the levels of liver-impairing metabolites, including corticosterone (CORT). Mechanistically, L-aspartate treatment efficiently reversed CORT-mediated glucocorticoid receptor β (GRβ) signaling activation and subsequent transcriptional suppression of the mitochondrial genome by directly binding to the mitochondrial genome. Knockout of GRβ ameliorated corticosterone-mediated mitochondrial dysfunction and hepatocyte damage which also weakened the improvements of L-aspartate in suppressing GRβ signaling. These data suggest that L-aspartate ameliorates hepatic fibrosis by suppressing GRβ signaling via rebalancing cholesterol-steroid metabolism, would be an ideal candidate for clinical liver fibrosis treatment.
Duavee® which is the combination of the selective estrogen receptor modulator (SERM) bazedoxifene plus conjugated estrogens is an FDA approved drug for treatment of hot-flashes and prevention of osteoporosis in postmenopausal women. In a single arm pilot study 6 months of Duavee® was associated with improvement in several risk biomarkers including benign breast tissue proliferation, mammographic fibroglandular volume, and progesterone in women in late menopause transition and at high risk for development of breast cancer. Prior to opening a planned randomized Phase IIB trial of 6 months of Duavee® vs placebo in high risk women with hot-flashes followed by open label Duavee®, a pilot trial was initiated of 6 months of Duavee® vs wait-list control in symptomatic women (Study00145121; NCT04379024). This trial was also intended to provide additional imaging biomarker information from MRI which was not performed in the previous prior study. A finding on MRI of greater background parenchymal enhancement (BPE) in high risk women is positively associated with higher probability of developing breast cancer and is independent of fibroglandular volume. BPE is reduced by selective estrogen receptor modulators including tamoxifen. Change in MRI BPE over time was also investigated for women randomly assigned to either receive Duavee® or not (wait-list control), as well as exploration of fully automated breast MRI volumetric density measures.

Unfortunately, midway through the trial, Duavee® became no longer available due to an issue with packaging and dissolution of the active agents. As an alternative, this current protocol will utilize separate agents of bazedoxifene (as Vivant® available from Japan) plus conjugated estrogens (available in the US as Premarin®). The specific objectives are identical to those in Study00145121, with the exception that Duavee® has been replaced by BZA+CE. The intent is to combine the results of both trials for analysis.
Changes in patient status are assessed based at least in part on respiration parameters. A user can make selections regarding alert criteria options to be used in assessing patient status. Respiration is implantably sensed and respiration data is stored by an implantable device. A respiration parameter, such as respiration rate, is measured from the respiration data. The change in patient status is assessed by comparing the respiration parameter to the configured alert criteria. If the comparison of the respiration parameter and the configured alert criteria indicates a significant change in patient status, an alert signal is generated.
BACKGROUND: Lung adenocarcinoma (LUAD) is a fatal disease with metabolic abnormalities. The dysregulation of S100 calcium-binding protein A2 (S100A2), a member of the S100 protein family, is connected to the development of various cancers. The impact of S100A2 on the LUAD occurrence and metastasis, however, has not yet been reported. The functional mechanism of S100A2 on LUAD cell metastasis was examined in this article.
METHODS: The expression of TFAP2A and S100A2 in LUAD tissues and cells was analyzed by bioinformatics and qRT-PCR, respectively. The enrichment pathway analysis was performed on S100A2. Bioinformatics analysis determined the binding relationship between TFAP2A and S100A2, and their interaction was validated through dual-luciferase and chromatin immunoprecipitation experiments. Cell viability was determined using cell counting kit-8 (CCK-8). A transwell assay was performed to analyze the invasion and migration of cells. Immunofluorescence was conducted to obtain vimentin and E-cadherin expression, and a western blot was used to detect the expression of MMP-2, MMP-9, GLS, and GLUD1. The kits measured the NADPH/NADP ratio, glutathione (GSH)/glutathione disulfide (GSSG) levels, and the contents of glutamine, α-KG, and glutamate.
RESULTS: S100A2 was upregulated in LUAD tissues and cells, and S100A2 mediated glutamine metabolism to induce LUAD metastasis. Additionally, the transcriptional regulator TFAP2A was discovered upstream of S100A2, and TFAP2A expression was upregulated in LUAD, which indicated that TFAP2A promoted the S100A2 expression. The rescue experiment found that upregulation of S100A2 could reverse the inhibitory effects of silencing TFAP2A on glutamine metabolism and cell metastasis.
CONCLUSION: In conclusion, by regulating glutamine metabolism, the TFAP2A/S100A2 axis facilitated LUAD metastasis. This suggested that targeting S100A2 could be beneficial for LUAD treatment.
Hawaii's Healthy Start Program (HSP) is a well-respected home visiting program for families at risk for abuse of their newborn children. The program incorporates early identification of at-risk families. Each family then begins receiving long-term home visitations. The home visiting component aims to promote child health and development and to prevent child abuse by improving family functioning and parenting. Home visitors are trained paraprofessionals working under professional supervision. The program includes both direct services and referrals to community resources. Direct services include providing emotional support to parents, encouraging them to seek needed professional help, teaching parents about child development, and role-modeling parenting skills and problem-solving techniques. In a previous study, at-risk families were randomly assigned to either HSP or no intervention. Evaluations were conducted at the time of the child's birth and at ages 1, 2, and 3 in order to assess the home environment and the development and well-being of the child. This study is a continuation study. Participants will include the original families from the previous study, as well as a new group of families who are not at risk for child abuse. By interviewing and observing these two groups of families, this study will evaluate the effectiveness of HSP in promoting children's mental health, cognitive and social-emotional development, and academic achievement in the first years of school.

All families will be evaluated on a yearly basis when the child is in 1st, 2nd, and 3rd grade. Interviews will be conducted with the parents, children, and teachers. Parent interviews will focus on family functioning, including mental health of the parents, parenting attitudes and behaviors, quality of the home environment, and any domestic violence or substance abuse that occurred. In addition, the child's health and development, as well as use of any community resources will be assessed. Interviews with the children and teachers will focus on assessing the child's behavior and emotional well-being. The family's home environment, the interaction between the parents and children, and the children's classroom behavior will be observed. Each child will also undergo developmental testing. All measurements will be collected at each yearly visit.
The invention discloses a PEGylated asparaginase as well as applications thereof to medicament preparation and clinic treatment. One molecule of asparaginase in the asparaginase modified by PEG is coupled to 13-45 molecules of PEG, and the PEG is straight-chain PEG whose average molecular weight is 2-20KDa. The PEGylated asparaginase is modified by PEG. The PEGylated asparaginase has the advantages of reduced immunogenicity, obviously prolonged half life, etc.; PEG and asparaginase are coupled more stable. Compared with branded drugs and generic drugs of commercially available PEGylated asparaginase, the PEGylated asparaginase has the advantages of more stable structure, firm combination of PEG, uneasy falling, higher homogeneity, and higher activity.
Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as Doxycycline Hyclate (doxycycline hydrochloride hemiethanolate hemihydrate)for oral administration.

The structural formula of doxycycline hyclate is

with a molecular formula of C22H24N2O8•HCl)2•C2H6O•H2Oand a molecular weight of 1025.87. The chemical designation for doxycycline hyclate is 4-(Dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro - 3,5,10, 12,12apentahydroxy-6-methyl-1,11-dioxo-2- naphthacen ecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellowish crystalline powder. Doxycycline hyclate is soluble in water, while doxycycline monohydrate is very slightly soluble in water.

Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert ingredients in the capsule formulations are: hard gelatin capsules (which contain FD&C Ble 1, gelatin, purified water and titanium dioxide ); microcrystalline cellulose ; magnesium stearate.
If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with \<2 DLTs in 6 patients.
OBJECTIVE: To derive reference distributions of estimated fetal weight (EFW) in twins relative to singletons.
METHODS: Gestational-age- and chorionicity-specific reference distributions for singleton percentiles and EFW were fitted to data on 4391 twin pregnancies with two liveborn fetuses from four European centers, including 3323 dichorionic (DC) and 1068 monochorionic diamniotic (MCDA) twin pregnancies. Gestational age was derived using the larger of the two crown-rump length measurements obtained during the first trimester of pregnancy. EFW was obtained from ultrasound measurements of head circumference, abdominal circumference and femur length using the Hadlock formula. Singleton percentiles were obtained using the Fetal Medicine Foundation population weight charts for singleton pregnancies. Hierarchical models were fitted to singleton Z-scores with autoregressive terms for serial correlations within the same fetus and between twins from the same pregnancy. Separate models were fitted for DC and MCDA twins.
RESULTS: Fetuses from twin pregnancies tended to be smaller than singletons at the earliest gestational ages (16 weeks for MCDA and 20 weeks for DC twins). This was followed by a period of catch-up growth until around 24 weeks. After that, both DC and MCDA twins showed reduced growth. In DC twins, the EFW corresponding to the 50th percentile was at the 50th percentile of singleton pregnancies at 23 weeks, the 43rd percentile at 28 weeks, the 32nd percentile at 32 weeks and the 22nd percentile at 36 weeks. In MCDA twins, the EFW corresponding to the 50th percentile was at the 36th percentile of singleton pregnancies at 24 weeks, the 29th percentile at 28 weeks, the 19th percentile at 32 weeks and the 12th percentile at 36 weeks.
CONCLUSIONS: In DC and, to a greater extent, MCDA twin pregnancies, fetal growth is reduced compared with that observed in singleton pregnancies. Furthermore, after 24 weeks, the divergence in growth trajectories between twin and singleton pregnancies becomes more pronounced as gestational age increases. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
Available treatments do not provide adequate relief for bladder pain syndrome/interstitial cystitis (BPS/IC), a chronic painful condition that affects 10 million women in the United States. The investigators plan to conduct a pilot randomized control study to determine the feasibility of conducting a combined CBT-hypnosis intervention vs. usual care in women with BPS/IC for a subgroup of women, we will determine the effect of specific hypnotic words on brain function using functional brain imaging. All women will have a pre-existing diagnosis of BPS/IC and their baseline pain prior to therapy and novel (arterial spin labeling) and more traditional (BOLD fMRI) neuroimaging techniques will be collected. Women in the hypnosis group will undergo treatment with three in-person hypnotherapy sessions in addition to a mobile web-based hypnosis application. Women in the usual care group will continue their usual care for BPS/IC. Subjects in both groups will complete a variety of questionnaires on bladder pain, urinary symptoms, sleep, mood, affect, disability, and sexual function before and after treatment. The first follow up visit will occur at the end of treatment (4 weeks after randomization). A select group of patients who are eligible to undergo neuroimaging will be invited to participate in neuroimaging after the first follow up visit. Data will also be collected at a second follow up visit at 2 months after randomization.
Despite intensive research efforts, there are still no simple and effective screening tools to detect early lung cancer. The majority of newly diagnosed patients have higher stage, often disseminated, non-resectable disease. A better understanding of the natural biology and molecular abnormalities in early lung lesions may aid in the development of more effective screening tools. The Lung Imaging Fluorescence Endoscopy (LIFE) is FDA approved as an adjunct to WL bronchoscopy for the screening of lung cancer.

Using the LIFE unit, this study will set the stage for the collection of a unique set of biopsy specimens that will be used to learn more about the natural biology and molecular changes in early lung lesions. We will study abnormalities in p53 by immunohistochemistry and by molecular analyses. The p53 results will be compared with histological grade and with genomic instability. Measures for genomic instability will be the loss of chromosomal information and cellular aneuploidy. Recent advances in molecular pathology, such as the development of Laser Capture Microdissection (LCM), have made the molecular profiling of these extremely small lesions feasible. The information obtained by these techniques will be used for comparison with clinical and exposure information. Future plans include the culturing of bronchial epithelial cells to study genomic instability in the multistep process of cancer progression. It is our hope that the application of these new technologies will improve the early detection of human lung cancer and provide insight into the natural biology and molecular changes of early lung lesions which may progress towards overt cancers.
The invention discloses paste, emulsifiable paste and liquid medicine used for treating verrucous diseases including verruca plana, verruca vulgaris, condyloma acuminata, verruca plantaris, verruca filiformis, verruca digitalis and periungual wart, etc. Fat-soluble naphthoquinone alkannin, the effective component of radix macrotomiae, is adopted as the core of the invention. The fat-soluble naphthoquinone alkannin has an effect on anti-HPV. The main components of prescription by mass percent are as follows: 0.05 to 1.2 percent of the naphthoquinone alkannin, 0.2 to 0.8 percent of allantoin, 0.1 to 2 percent of Vitamin E, emulsifier and humectant, and the like, which constitute the paste, the emulsifiable paste and the liquid medicine. A test proves that the invention can treat the various verrucous diseases, including the verruca plana, the verruca vulgaris, the condyloma acuminata, the verruca plantaris, the verruca filiformis, the verruca digitalis and the periungual wart, and the like, and a curative effect is over 86 percent, so the invention is good medicine for treating the various verrucous diseases without any adverse reaction. The medicine with the high content of the naphthoquinone alkannin treats the condyloma acuminata best and has an effect on diminishing the inflammation of a hurt on an afflicted part, thus sterilizing the hurt and stimulating the healing of the hurt without leaving a scar.
An improved vector which upon introduction into a suitable host containing the thermolabile repressor CI renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following:  the promoter and operator P L O L from lambda bacteriophage; the N utilization site; a first restriction enzyme site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzme site for inserting the gene in phase with the ATG initiation codon; an origin of replication and either a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host or a fragment designated cI434 which includes the gene for the cI434 repressor protein and its associated promoter and operator.  The distance between the 3' end of P L O L and the 5' end of the N utilization site is less than about 80 base pairs. The distance between the 3' end of the N utilization site and the 5' end of the ribosomal binding site is less than about 300 base pairs.  Vectors of the invention may also include a T1T2 rRNA transcription termination sequence located 3' of the second restriction enzyme site.  The inventive vectors may have origin of replications capable of autonomous production in the host of at least 400 constitutive copies.  Plasmids have been constructed from the vectors and used to produce bovine, chicken, porcine and human growth hormones, human apolipoprotein E and human superoxide dismutase and analogs thereof in host cells.  Such superoxide dismutase or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs and prevent neurological injury.  Enzymatically active eucaryotic superoxide dismutase or an analog thereof may also be produced by an improved method of this invention which employs a production medium having a concentration of Cu++ greater than about about 2ppm.  The invention also concerns improved methods of recovering purified enzymatically active eucaryotic superoxide dismutase or analogs thereof.